Hempel, LouisaLouisaHempelMolnar, JakobJakobMolnarRobert, SebastianSebastianRobertVeloso, JuliaJuliaVelosoTrepotec, ZeljkaZeljkaTrepotecEnglisch, SofieSofieEnglischWeinzierl, PhilipPhilipWeinzierlSchick, CordulaCordulaSchickMilani, ValeriaValeriaMilaniSchweneker, KatrinKatrinSchwenekerFleischmann, BastianBastianFleischmannScheiber, JosefJosefScheiberGandorfer, BeateBeateGandorferKleespies, AxelAxelKleespiesHempel, DirkDirkHempelRiedmann, KristinaKristinaRiedmannPiehler, ArminArminPiehler2022-03-062022-03-062021https://publica.fraunhofer.de/handle/publica/26602210.1053/j.seminoncol.2020.12.003SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers' specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.enSARS-CoV2 antibody developmentCOVID-19cancerimmunity004670journal article